Structural and functional aspects of C1-inhibitor

Immunobiology

Volumn 205, Issue 4-5, 2002, Pages 518-533

  Bos, I G A ^a   Hack, C E ^a,b   Abrahams, J ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; COMPLEMENT COMPONENT C1; COMPLEMENT INHIBITOR; HEPARIN COFACTOR II; PLASMINOGEN ACTIVATOR INHIBITOR 3; SERINE PROTEINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; BLOOD CLOTTING; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; GLYCOSYLATION; METHODOLOGY; MOLECULAR MODEL; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING;

EID: 0036747220     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00151     Document Type: Article

References (63)

1. COOPER, N. R. 1985. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37: 151.
2. SCHAPIRA, M., A. DE AGOSTINI, J. A. SCHIFFERLI, and R. W. COLMAN. 1985. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement 2: 111.
3. Sim, R. B., A. REBOUL, G. J. ARLAUD, C. L. VILLIERS, and M. G. COLOMB. 1979. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett. 97: 111.
4. CHAN, J. Y, C. E. BURROWES, F. M. HABAL, and H. Z. MOVAT. 1977. The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors. Biochem. Biophys. Res. Commun. 74: 150.
5. PIXLEY, R. A., M. SCHAPIRA, and R. W. COLMAN. 1985. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 260: 1723.
6. SCHAPIRA, M., C. F., SCOTT, and R. W. COLMAN. 1982. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69: 462.
7. VAN DER GRAAF, F., J. A. KOEDAM, and B. N. BOUMA. 1983. Inactivation of kallikrein in human plasma. J. Clin. Invest. 71: 149.
8. WUILLEMIN, W. A., M. MINNEMA, J. C. MEIJERS, D. ROEM, A. J. EERENBERG, J. H. NUIJENS, H. TEN CATE, and C. E. HACK. 1995. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 85: 1517.
9. MATSUSHITA, M., S. THIEL, J. C. JENSENIUS, I. TERAI, and T. FUJITA. 2000. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol. 165: 2637.
10. CALIEZI, C., W. A. WUILLEMIN, S. ZEERLEDER, M. REDONDO, B. EISELE, and C. E. HACK. 2000. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52: 91.
11. RENT, R., R. MYHRMAN, B. A. FIEDEL, and H. GEWURZ. 1976. Potentiation of C1-esterase inhibitor activity by heparin. Clin. Exp. Immunol. 23: 264.
12. WUILLEMIN, W. A., V. H. TE, Y. T. LUBBERS, C. P. DE RUIG, E. ELDERING, and C. E. HACK. 1997. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J. Immunol. 159: 1953.
13. BOS, I. G., G. J. VAN MIERLO, W. K. BLEEKER, G. M. RIGTER, V. H. TE, G. DICKNEITE, and C. E. HACK. 2001. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int. Immunopharmacol. 1: 1583.
14. BOCK, S. C., K. SKRIVER, E. NIELSEN, H. C. THOGERSEN, B. WIMAN, V. H. DONALDSON, R. L. EDDY, J. MARRINAN, E. RADZIEJEWSKA, and R. HUBER. 1986. Human C1 inhibitor: primary structure, CDNA cloning, and chromosomal localization. Biochemistry 25: 4292.
15. PERKINS, S. J., K. F. SMITH, S. AMATAYAKUL, D. ASHFORD, T. W. RADEMACHER, R. A. DWEK, P. J. LACHMANN, and R. A. HARRISON. 1990. Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. J. Mol. Biol. 214: 751.
16. PERKINS, S. J. 1993. Three-dimensional structure and molecular modelling of C1-inhibitor. Behring. Inst. Mitt. 63.
17. KOMIYAMA, T, C. A. RAY, D. J. PICKUP, A. D. HOWARD, N. A. THORNBERRY, E. P. PETERSON, and G. SALVESEN. 1994. Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition. J. Biol. Chem. 269: 19331.
18. HUNTINGTON, J. A., R. J. READ, and R. W. CARRELL. 2001. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407: 923.
19. HUNTINGTON, J. A., and R. W. CARRELL. 2001. The serpins: nature's molecular mousetraps. Sci. Prog. 84: 125.
20. STORM, D., J. HERZ, P. TRINDER, and M. LOOS. 1997. C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J. Biol. Chem. 272: 31043.
21. DE SMET, B. J., J. P. DE BOER, J. AGTERBERG, G. RIGTER, W. K. BLEEKER, and C. E. HACK. 1993. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 81: 56.
22. WHISSTOCK, J., R. SKINNER, and A. M. LESK. 1998. An atlas of serpin conformations. Trends. Biochem. Sci. 23; 63.
23. CARRELL, R. W. 1999. How serpins are shaping up. Science 285: 1861.
24. BERMAN, H. M., J. WESTBROOK, Z. FENG, G. GILLILAND, T. N. BHAT, H. WEISSIG, I. N. SHINDYALOV, and P. E. BOURNE. 2000. The protein data bank [In Process Citation]. Nucleic. Acids. Res. 28: 235.
25. ELLIOTT, P. R., J. P. ABRAHAMS, and D. A. LOMAS. 1998. Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J. Mol. Biol. 275: 419.
26. LI, J., Z. WANG, B. CANAGARAJAH, H. JIANG, M. KANOST, and E. J. GOLDSMITH. 1999. The structure of active serpin 1K from Manduca sexta. Structure. Fold. Des. 7: 103.
27. SKINNER, R., J. P. ABRAHAMS, J. C. WHISSTOCK, A. M. LESK, R. W. CARRELL, and M. R. WARDELL. 1997. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J. Mol. Biol. 266: 601.
28. STEIN, P. E., A. G. LESLIE, J. T. FINCH, and R. W. CARRELL. 1991. Crystal structure of uncleaved ovalbumin at 1.95 A resolution. J. Mol. Biol. 221: 941.
29. JEANMOUGIN, F., J. D. THOMPSON, M. GOUY, D. G. HIGGINS, and T. J. GIBSON. 1998. Multiple sequence alignment with Clustal X. Trends. Biochem. Sci. 23: 403.
30. THOMPSON, J. D., D. G. HIGGINS, and T. J. GIBSON. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22: 4673.
31. JONES, T. A., J. Y Zou, S. W. COWAN, and KJELDGAARD. 1991. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47: 110.
32. VRIEND, G. 1990. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 8: 52.
33. TATUSOVA, T. A., and T. L. MADDEN. 1999. BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences (published erratum appears in FEMS Microbiol Lett 1999 Aug 1;177(1): 187-8]. FEMS Microbiol. Lett. 174: 247.
34. ALTSCHUL, S. F., T. L. MADDEN, A. A. SCHAFFER, J. ZHANG, Z. ZHANG, W. MILLER, and D. J. LIPMAN. 1997. Gapped BLAST and PSI-BLAST. a new generation of protein database search programs. Nucleic Acids Res. 25: 3389.
35. SALVESEN, G. S., J. J. CATANESE, L. F. KRESS, and J. TRAVIS. 1985. Primary structure of the reactive site of human C1-inhibitor. J. Biol. Chem. 260: 2432.
36. HE, S., R. B. SIM, and K. WHALEY. 1997. A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex. FEBS Lett. 405: 42.
37. HE, S., J. C. YANG, S. TSANG, R. B. SIM, and K. WHALEY. 1997. Role of the distal hinge region of C1-inhibitor in the regulation of C1s activity. FEBS Lett. 412: 506.
38. + helix in heparin binding to protein C inhibitor. Thromb. Haemost. 75: 760.
39. SHIRK, R. A., M. G. ELISEN, J. C. MEIJERS, and E C. CHURCH. 1994. Role of the H helix in heparin binding to protein C inhibitor. J. Biol. Chem. 269: 28690.
40. NEESE, L. L., C. A. WOLFE, and F. C. CHURCH. 1998. Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor. Arch. Biochem. Biophys. 355: 101.
41. GUEX, N., and M. C. PEITSCH. 1997. SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis 18: 2714.
42. PEITSCH, M. C. 1996. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem. Soc. Trans. 24: 274.
43. REBOUL, A., M. H. PRANDINI, and M. G. COLOMB. 1987. Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties. Biochem. J. 244: 117.
44. ZAHEDI, R., K. S. AULAK, E. ELDERING, and A. E. DAVIS. 1996. Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251. J. Biol. Chem. 271: 24307.
45. MINTA, J. O. 1981. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J. Immunol. 126: 245.
46. COUTINHO, M., K. S. AULAK, and A. E. DAVIS. 1994. Functional analysis of the serpin domain of C1 inhibitor. J. Immunol. 153: 3648.
47. SIMONOVIC, I., and P. A. PATSTON. 2000. The native metastable fold of C1-inhibitor is stabilized by disulfide bonds. Biochim. Biophys. Acta 1481: 97.
48. ZURAW, B. L., and J. HERSCHBACH. 2000. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J. Allergy Clin. Immunol. 105: 541.
49. JIN, L., J. P. ABRAHAMS, R. SKINNER, M. PETITOU, R. N. PIKE, and R. W. Carrell. 1997. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. USA 94: 14683.
50. WHINNA, H. C., M. A. BLINDER, M. SZEWCZYK, D. M. TOLLEFSEN, and F. C. CHURCH. 1991. Role of lysine 173 in heparin binding to heparin cofactor II. J. Biol. Chem. 266: 8129.
51. WUILLEMIN, W A., E. ELDERING, F. CITARELLA, C. P. DE RUIG, H. TEN CATE, and C. E. HACK 1996. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. 271: 12913.
52. ZAHEDI, R., J. J. BISSLER, A. E. DAVIS, C. ANDREADIS, and J. J. WISNIESKI. 1995. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443→Val substitution and functional analysis of the recombinant mutant protein. J. Clin. Invest. 95: 1299.
53. ZAHEDI, R., J. WISNIESKI, and A. E. DAVIS. 1997. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases. J. Immunol. 159: 983.
54. ELDERING, E., C. C. HUIJBREGTS, J. H. NUIJENS, A. J. VERHOEVEN, and C. E. HACK. 1993. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. J. Clin. Invest. 91: 1035.
55. DAVIS, A. E. 1997. C1 inhibitor. Functional analysis of naturally-occurring mutant proteins. Adv. Exp. Med. Biol. 425: 185-194.
56. AULAK, K. S., E. ELDERING, C. E. HACK, Y. P. LUBBERS, R. A. HARRISON, A. MAST, M. CICARDI, and A. E. DAVIS. 1993. A hinge region mutation in C1-inhibitor (Ala4362[Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J. Biol. Chem. 268: 18088.
57. ELDERING, E., E. VERPY, D. ROEM, T. MEO, and M. TOSI. 1995. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop over insertion and subsequent .multimerization. J. Biol. Chem. 270: 2579.
58. VERPY, E., E. COUTURE-TOSI, E. ELDERING, M. LOPEZ-TRASCASA, P. SPATH, T. MEO, and M. TOSI. 1995. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function. J. Clin. Invest. 95: 350.
59. BOWEN, B., J. J. HAWK, S. SIBUNKA, S. HOVICK, and J. M. WEILER. 2001. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin. Immunol. 98: 157.
60. BISSLER, J. J., K. S. AULAK, V. H. DONALDSON, F. S. ROSEN, M. CICARDI, R. A. HARRISON, and A. E. DAVIS. 1997. Molecular defects in hereditary angioneurotic edema. Proc. Assoc. Am. Physicians 109: 164.
61. VERPY, E., M. BIASOTTO, M. BRAI. G. MISIANO, T. MEO, and M. TOSI. 1996. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am. J. Hum. Genet. 59: 308.
62. HE, S., S. TSANG, J. NORTH, N. CHOHAN, R. B. SIM, and K. WHALEY. 1996. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. J. Immunol. 156: 2009.
63. ZAHEDI, R., R. C. MACFARLANE, J. J. WISNIESKI, and A. E. DAVIS. 2001. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition. J. Immunol. 167:1500.